FDA Approves New Treatments
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated “This is an epic moment for the treatment of ATTR amyloidosis. We are very excited and hopeful for the expanding landscape of ATTR amyloidosis by the approval of tafamidis, the first drug approved for ATTR cardiomyopathy. Tafamidis will have a tremendous impact on patients with both hereditary and wildtype ATTR amyloidosis. Given the complexities […]